Pharmacogenetics of a PARP inhibitor ABT-888 metabolic pathway
Li J, Sha X, LoRusso P. Pharmacogenetics of a PARP inhibitor ABT-888 metabolic pathway. Journal Of Clinical Oncology 2009, 27: e14556-e14556. DOI: 10.1200/jco.2009.27.15_suppl.e14556.Peer-Reviewed Original ResearchGenetic variantsMetabolic pathwaysDNA break repairABT-888Significant genetic variantsTherapeutic outcomesBreak repairCytochrome P450Ongoing phase I trialMolecular basisWild-type CYP2D6Advanced solid tumorsPhase I trialRecombinant human cytochrome P450DNA damageHuman liver microsomesMetabolite formationVariant enzymeMultiple cytotoxic agentsTumor drug concentrationsPARP activityFunctional significanceMajor enzymePredominant enzymeHuman cytochrome P450